Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasma cell | 3 studies | 23% ± 5% |
Insufficient scRNA-seq data for expression of FICD at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 522.49 | 2638 / 2642 | 100% | 15.79 | 705 / 705 |
prostate | 100% | 515.34 | 244 / 245 | 100% | 15.34 | 501 / 502 |
breast | 100% | 360.53 | 457 / 459 | 100% | 9.92 | 1114 / 1118 |
adrenal gland | 100% | 1113.67 | 258 / 258 | 99% | 16.73 | 228 / 230 |
kidney | 100% | 409.47 | 89 / 89 | 99% | 8.52 | 889 / 901 |
thymus | 100% | 433.63 | 652 / 653 | 99% | 8.89 | 596 / 605 |
pancreas | 100% | 1035.70 | 328 / 328 | 98% | 7.00 | 175 / 178 |
stomach | 100% | 483.17 | 358 / 359 | 98% | 5.18 | 281 / 286 |
intestine | 100% | 346.11 | 966 / 966 | 97% | 4.98 | 511 / 527 |
skin | 97% | 324.21 | 1752 / 1809 | 98% | 8.88 | 462 / 472 |
lung | 96% | 461.89 | 552 / 578 | 99% | 7.21 | 1140 / 1155 |
bladder | 100% | 452.19 | 21 / 21 | 92% | 4.56 | 465 / 504 |
uterus | 98% | 446.39 | 167 / 170 | 94% | 5.63 | 431 / 459 |
ovary | 99% | 343.76 | 179 / 180 | 92% | 4.25 | 397 / 430 |
liver | 94% | 667.38 | 213 / 226 | 96% | 6.50 | 391 / 406 |
esophagus | 98% | 290.99 | 1412 / 1445 | 91% | 4.01 | 167 / 183 |
lymph node | 0% | 0 | 0 / 0 | 100% | 7.43 | 29 / 29 |
spleen | 100% | 505.20 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.79 | 1 / 1 |
adipose | 100% | 412.44 | 1200 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 446.38 | 1328 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 5.29 | 43 / 45 |
heart | 95% | 254.99 | 815 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 93% | 6.01 | 74 / 80 |
muscle | 77% | 169.20 | 619 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 48% | 196.64 | 443 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1903894 | Biological process | regulation of IRE1-mediated unfolded protein response |
GO_0006986 | Biological process | response to unfolded protein |
GO_0034260 | Biological process | negative regulation of GTPase activity |
GO_0044602 | Biological process | protein deadenylylation |
GO_0018117 | Biological process | protein adenylylation |
GO_0034976 | Biological process | response to endoplasmic reticulum stress |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0030544 | Molecular function | Hsp70 protein binding |
GO_0051087 | Molecular function | protein-folding chaperone binding |
GO_0044603 | Molecular function | protein adenylylhydrolase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0070733 | Molecular function | AMPylase activity |
GO_0005524 | Molecular function | ATP binding |
Gene name | FICD |
Protein name | Protein adenylyltransferase FICD (EC 2.7.7.108) (AMPylator FICD) (De-AMPylase FICD) (EC 3.1.4.-) (FIC domain-containing protein) (Huntingtin yeast partner E) (Huntingtin-interacting protein 13) (HIP-13) (Huntingtin-interacting protein E) FIC domain protein adenylyltransferase |
Synonyms | HIP13 UNQ3041/PRO9857 HYPE |
Description | FUNCTION: Protein that can both mediate the addition of adenosine 5'-monophosphate (AMP) to specific residues of target proteins (AMPylation), and the removal of the same modification from target proteins (de-AMPylation), depending on the context (By similarity). The side chain of Glu-231 determines which of the two opposing activities (AMPylase or de-AMPylase) will take place (By similarity). Acts as a key regulator of the ERN1/IRE1-mediated unfolded protein response (UPR) by mediating AMPylation or de-AMPylation of HSPA5/BiP . In unstressed cells, acts as an adenylyltransferase by mediating AMPylation of HSPA5/BiP at 'Thr-518', thereby inactivating it (By similarity). In response to endoplasmic reticulum stress, acts as a phosphodiesterase by mediating removal of ATP (de-AMPylation) from HSPA5/BiP at 'Thr-518', leading to restore HSPA5/BiP activity (By similarity). Although it is able to AMPylate RhoA, Rac and Cdc42 Rho GTPases in vitro, Rho GTPases do not constitute physiological substrates . . |
Accessions | ENST00000549641.1 ENST00000552758.1 F8VZ74 Q9BVA6 ENST00000552695.6 H0YIR6 J3KP49 ENST00000361549.2 |